Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SILO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
6.86 | 7.08 | 7.67 | 11.37 | 10.26 | 1.13 | 0.12 | 0.57 | 1.61 | 1.21 |
Receivables |
— | — | — | — | — | — | — | — | — | 0.06 |
Inventory |
— | — | — | — | — | — | 0.16 | 0.03 | — | — |
Other current assets |
0.32 | — | — | 0.14 | 0.15 | 0.27 | 0.02 | 0.03 | — | — |
Total current assets |
7.39 | 7.11 | 7.68 | 11.57 | 10.40 | 1.43 | 0.49 | 0.63 | 1.64 | 1.30 |
Long-term receivables |
— | — | — | — | 0.06 | — | — | 0.20 | — | — |
Goodwill and Intangible Assets (Total) |
0.22 | 0.24 | — | — | — | — | — | 0.03 | — | — |
Long-term assets (Other) |
— | 0.06 | 0.07 | 0.07 | 0.03 | — | — | — | — | — |
Total non-current assets |
0.22 | 0.30 | 0.07 | 0.07 | 0.09 | — | — | 0.23 | — | — |
Total Assets |
7.61 | 7.41 | 7.75 | 11.64 | 10.49 | 1.43 | 0.49 | 0.86 | 1.64 | 1.30 |
Notes Payable |
— | — | — | — | — | 0.01 | — | — | — | — |
Accounts Payable |
0.58 | 1.58 | 0.70 | 0.36 | 0.42 | 0.13 | 0.05 | 0.03 | 0.04 | 0.05 |
Current Part of Debt |
— | — | — | — | — | — | 0.06 | 0.02 | — | — |
Current Revenue (Deferred) |
0.07 | 0.07 | 0.07 | 0.07 | 0.07 | — | — | — | — | — |
Total current liabilities |
0.65 | 1.66 | 0.78 | 0.44 | 0.49 | 0.14 | 0.12 | 0.05 | 0.04 | 0.05 |
Long Term Debt (Total) |
— | — | — | — | — | 0.00 | — | — | — | — |
Non-current Revenue (Deferred) |
0.65 | 0.72 | 0.79 | 0.87 | 0.94 | — | — | — | — | — |
Preferred Shares of Subsidiary (Mandatory, Redeemable) |
— | — | — | — | — | — | 0.40 | 0.40 | 0.40 | 0.40 |
Total non-current liabilities |
0.65 | 0.72 | 0.79 | 0.87 | 0.94 | 0.00 | 0.40 | 0.40 | 0.40 | 0.40 |
Total liabilities |
1.30 | 2.38 | 1.57 | 1.30 | 1.43 | 0.15 | 0.52 | 0.45 | 0.44 | 0.45 |
Additional Paid In Capital |
25.79 | 20.30 | 17.53 | 17.51 | 12.32 | 7.03 | 2.63 | 2.05 | 1.87 | 1.87 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
Retained Earnings |
(19.49) | (15.26) | (10.87) | (7.17) | (3.26) | (5.76) | (2.66) | (1.64) | — | — |
Treasury Stock |
— | — | 0.47 | — | — | — | — | — | — | — |
Common Equity (Total) |
6.31 | 5.03 | 6.18 | 10.34 | 9.06 | 1.28 | (0.02) | 0.41 | 1.20 | 0.85 |
Shareholders Equity (Total) |
6.31 | 5.03 | 6.18 | 10.34 | 9.06 | 1.28 | (0.02) | 0.41 | 1.20 | 0.85 |
Shareholders Equity and Liabilities (Total) |
7.61 | 7.41 | 7.75 | 11.64 | 10.49 | 1.43 | 0.49 | 0.86 | 1.64 | 1.30 |
Shares (Common) |
0.89 | 0.30 | 0.19 | 0.21 | 0.13 | 5.68 | 1.57 | 1.56 | 3.34 | 3.34 |
Shares (Preferred) |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Shareholders Equity (Tangible) |
6.09 | 4.79 | 6.18 | 10.34 | 9.06 | 1.28 | (0.02) | 0.38 | 1.20 | 0.85 |
Net Debt |
(6.86) | (7.08) | (7.67) | (11.37) | (10.26) | (1.12) | (0.06) | (0.54) | (1.61) | (1.21) |
Total Debt |
— | — | — | — | — | 0.00 | 0.06 | 0.02 | — | — |